BioLineRx
Oct 06, 2017
C-X-C Chemokine Receptor Inhibitors–The Emerging Therapeutic Agents
C-X-C chemokine receptors (CXCR) is a family of G protein-coupled receptors that comprises of a large subfamily of the rhodopsin superfamily of 7-transmembrane domain receptors. Two types of chemokine receptors have been identified including monogamous chemokine receptors (bind to only one specific chemokine) and pr...
Read More...
Aug 31, 2016
BI & Duke Clinical Research Institute have expansion; BioInvent Inks Mfg. Pact; Elite Pharma, SunGen Pharma in Development & License Deal; Boehringer and Saniona Develop new Compounds; BioLineRx and I-Bridge Capital Establish; Alliance between Harvard and Tata Companies; Innovative Targeting Solutions and Johnson & Johnson Innovation collaborate
Boehringer Ingelheim Pharmaceuticals and the Duke Clinical Research Institute have expanded their collaboration to create the largest patient registry for Idiopathic Pulmonary Fibrosis (IPF) The IPF-PRO Registry will be widened to cover 1500 patients spread over 45 clinical sites which will stimulate understand...
Read More...
Aug 24, 2016
Bristol Meyers Squibb & AbbVie partner; BioLineRx’s collaboration with MD Anderson Cancer Centre; Partnership between Regeneron Pharmaceuticals and Adicet Bio; Immunotherapy Target Unique Mutations in cancer
Partnership between Bristol Meyers Squibb and AbbVie aims to evaluate the Combination of Rova-T plus Opdivo and Opdivo plus Yervoy Regimen Bristol Meyers Squibb and AbbVie have undergone an oncology clinical collaboration to develop a treatment option for patients with relapsed extensive-stage small cell lung cancer...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
